Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23280600 | 1.00 | ESR1 (0.75) | ESR1 | |
| SCHEMBL29358188 | 1.00 | ESR1 (0.75) | ESR1 | |
| SCHEMBL30123889 | 0.92 | ESR1 (0.76) | ESR1 | |
| SCHEMBL17839580 | 0.92 | ESR1 (0.76) | ESR1 | |
| SCHEMBL21725032 | 0.92 | ESR1 (0.76) | ESR1 | |
| Palazestrant SCHEMBL20528170 | 0.88 | ESR1 (0.78) | ESR1 | |
| Palazestrant SCHEMBL24885107 | 0.88 | ESR1 (0.78) | ESR1 | |
| Palazestrant SCHEMBL23280512 | 0.88 | ESR1 (0.78) | ESR1 | |
| Palazestrant SCHEMBL30128723 | 0.88 | ESR1 (0.78) | ESR1 | |
| SCHEMBL25002345 | 0.86 | ESR1 (1.00) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220370421-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11229630-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229630-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3355884-B1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210059991-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210059991-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10624878-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10624878-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190247372-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190247372-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10292971-B2 | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10292971-B2 | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180289679-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624878-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-20190247372-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-10292971-B2 | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-20180289679-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-11229630-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-20220370421-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
| US-20210059991-A1 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.